The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Neurotrophic Keratitis Therapeutics Market Research Report 2025

Global Neurotrophic Keratitis Therapeutics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :

Report Code : 1721821

No of Pages : 87

Ask Your Query

Report Description
Table of Content

Synopsis

Neurotrophic keratitis?(NK) is a degenerative disease of the cornea caused by damage of the trigeminal nerve, which results in impairment of corneal sensitivity, spontaneous corneal epithelium breakdown, poor corneal healing and development of corneal ulceration, melting and perforation.

The global Neurotrophic Keratitis Therapeutics market was valued at US$ 852 million in 2023 and is anticipated to reach US$ 1514.9 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.

North American market for Neurotrophic Keratitis Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Neurotrophic Keratitis Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Neurotrophic Keratitis Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Neurotrophic Keratitis Therapeutics include Dompe farmaceutici S.p.A.,, Allergan,, ReGenTree, LLC, Alcon,, Bausch & Lomb Incorporated (Bausch Health Companies Inc.),, CONTACARE,, OHTO Pharmaceutical Co., Ltd.,, Pfizer, Inc.,, Neuroptika and Santen Pharmaceutical Co., Ltd.,, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Neurotrophic Keratitis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurotrophic Keratitis Therapeutics.

Report Scope

The Neurotrophic Keratitis Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurotrophic Keratitis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neurotrophic Keratitis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

Dompe farmaceutici S.p.A.,
Allergan,
ReGenTree, LLC, Alcon,
Bausch & Lomb Incorporated (Bausch Health Companies Inc.),
CONTACARE,
OHTO Pharmaceutical Co., Ltd.,
Pfizer, Inc.,
Neuroptika
Santen Pharmaceutical Co., Ltd.,
Johnson & Johnson,
Grand Pharma (China) Co., Ltd., and
Zhejiang CONBA Pharmaceutical Co., Ltd.

Segment by Type

Drugs
Surgical Intervention

Segment by Application

Hospital
Clinic

By Region

North America (United States, Canada)
Europe (Germany, France, U.K., Italy, Netherlands)
Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurotrophic Keratitis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurotrophic Keratitis Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Drugs
1.2.3 Surgical Intervention
1.3 Market by Application
1.3.1 Global Neurotrophic Keratitis Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurotrophic Keratitis Therapeutics Market Perspective (2019-2030)
2.2 Neurotrophic Keratitis Therapeutics Growth Trends by Region
2.2.1 Global Neurotrophic Keratitis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurotrophic Keratitis Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Neurotrophic Keratitis Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Neurotrophic Keratitis Therapeutics Market Dynamics
2.3.1 Neurotrophic Keratitis Therapeutics Industry Trends
2.3.2 Neurotrophic Keratitis Therapeutics Market Drivers
2.3.3 Neurotrophic Keratitis Therapeutics Market Challenges
2.3.4 Neurotrophic Keratitis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurotrophic Keratitis Therapeutics Players by Revenue
3.1.1 Global Top Neurotrophic Keratitis Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Neurotrophic Keratitis Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Neurotrophic Keratitis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurotrophic Keratitis Therapeutics Revenue
3.4 Global Neurotrophic Keratitis Therapeutics Market Concentration Ratio
3.4.1 Global Neurotrophic Keratitis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurotrophic Keratitis Therapeutics Revenue in 2023
3.5 Neurotrophic Keratitis Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurotrophic Keratitis Therapeutics Product Solution and Service
3.7 Date of Enter into Neurotrophic Keratitis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurotrophic Keratitis Therapeutics Breakdown Data by Type
4.1 Global Neurotrophic Keratitis Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Neurotrophic Keratitis Therapeutics Forecasted Market Size by Type (2025-2030)
5 Neurotrophic Keratitis Therapeutics Breakdown Data by Application
5.1 Global Neurotrophic Keratitis Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Neurotrophic Keratitis Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurotrophic Keratitis Therapeutics Market Size (2019-2030)
6.2 North America Neurotrophic Keratitis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurotrophic Keratitis Therapeutics Market Size by Country (2019-2024)
6.4 North America Neurotrophic Keratitis Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurotrophic Keratitis Therapeutics Market Size (2019-2030)
7.2 Europe Neurotrophic Keratitis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurotrophic Keratitis Therapeutics Market Size by Country (2019-2024)
7.4 Europe Neurotrophic Keratitis Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurotrophic Keratitis Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Neurotrophic Keratitis Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurotrophic Keratitis Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurotrophic Keratitis Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurotrophic Keratitis Therapeutics Market Size (2019-2030)
9.2 Latin America Neurotrophic Keratitis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurotrophic Keratitis Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Neurotrophic Keratitis Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurotrophic Keratitis Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Neurotrophic Keratitis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurotrophic Keratitis Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurotrophic Keratitis Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dompe farmaceutici S.p.A.,
11.1.1 Dompe farmaceutici S.p.A., Company Detail
11.1.2 Dompe farmaceutici S.p.A., Business Overview
11.1.3 Dompe farmaceutici S.p.A., Neurotrophic Keratitis Therapeutics Introduction
11.1.4 Dompe farmaceutici S.p.A., Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.1.5 Dompe farmaceutici S.p.A., Recent Development
11.2 Allergan,
11.2.1 Allergan, Company Detail
11.2.2 Allergan, Business Overview
11.2.3 Allergan, Neurotrophic Keratitis Therapeutics Introduction
11.2.4 Allergan, Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.2.5 Allergan, Recent Development
11.3 ReGenTree, LLC, Alcon,
11.3.1 ReGenTree, LLC, Alcon, Company Detail
11.3.2 ReGenTree, LLC, Alcon, Business Overview
11.3.3 ReGenTree, LLC, Alcon, Neurotrophic Keratitis Therapeutics Introduction
11.3.4 ReGenTree, LLC, Alcon, Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.3.5 ReGenTree, LLC, Alcon, Recent Development
11.4 Bausch & Lomb Incorporated (Bausch Health Companies Inc.),
11.4.1 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Company Detail
11.4.2 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Business Overview
11.4.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Therapeutics Introduction
11.4.4 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.4.5 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Recent Development
11.5 CONTACARE,
11.5.1 CONTACARE, Company Detail
11.5.2 CONTACARE, Business Overview
11.5.3 CONTACARE, Neurotrophic Keratitis Therapeutics Introduction
11.5.4 CONTACARE, Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.5.5 CONTACARE, Recent Development
11.6 OHTO Pharmaceutical Co., Ltd.,
11.6.1 OHTO Pharmaceutical Co., Ltd., Company Detail
11.6.2 OHTO Pharmaceutical Co., Ltd., Business Overview
11.6.3 OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Therapeutics Introduction
11.6.4 OHTO Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.6.5 OHTO Pharmaceutical Co., Ltd., Recent Development
11.7 Pfizer, Inc.,
11.7.1 Pfizer, Inc., Company Detail
11.7.2 Pfizer, Inc., Business Overview
11.7.3 Pfizer, Inc., Neurotrophic Keratitis Therapeutics Introduction
11.7.4 Pfizer, Inc., Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.7.5 Pfizer, Inc., Recent Development
11.8 Neuroptika
11.8.1 Neuroptika Company Detail
11.8.2 Neuroptika Business Overview
11.8.3 Neuroptika Neurotrophic Keratitis Therapeutics Introduction
11.8.4 Neuroptika Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.8.5 Neuroptika Recent Development
11.9 Santen Pharmaceutical Co., Ltd.,
11.9.1 Santen Pharmaceutical Co., Ltd., Company Detail
11.9.2 Santen Pharmaceutical Co., Ltd., Business Overview
11.9.3 Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Therapeutics Introduction
11.9.4 Santen Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.9.5 Santen Pharmaceutical Co., Ltd., Recent Development
11.10 Johnson & Johnson,
11.10.1 Johnson & Johnson, Company Detail
11.10.2 Johnson & Johnson, Business Overview
11.10.3 Johnson & Johnson, Neurotrophic Keratitis Therapeutics Introduction
11.10.4 Johnson & Johnson, Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.10.5 Johnson & Johnson, Recent Development
11.11 Grand Pharma (China) Co., Ltd., and
11.11.1 Grand Pharma (China) Co., Ltd., and Company Detail
11.11.2 Grand Pharma (China) Co., Ltd., and Business Overview
11.11.3 Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Therapeutics Introduction
11.11.4 Grand Pharma (China) Co., Ltd., and Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.11.5 Grand Pharma (China) Co., Ltd., and Recent Development
11.12 Zhejiang CONBA Pharmaceutical Co., Ltd.
11.12.1 Zhejiang CONBA Pharmaceutical Co., Ltd. Company Detail
11.12.2 Zhejiang CONBA Pharmaceutical Co., Ltd. Business Overview
11.12.3 Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Therapeutics Introduction
11.12.4 Zhejiang CONBA Pharmaceutical Co., Ltd. Revenue in Neurotrophic Keratitis Therapeutics Business (2019-2024)
11.12.5 Zhejiang CONBA Pharmaceutical Co., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Global Support Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Hospital OT and X-Ray, Cathode Room Doors (Hermetically Sealed Door) Market Research Report 2025

Global Children\'s DHA Market Research Report 2025

Global Marine Derived Drugs Market Research Report 2025

Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}